BioNTech to continue focus on mRNA after founders exit

2026년 06월 08일

AI에 의해 보고됨

The Mainz company has made its first strategic decision following the founders departure and will stick with mRNA technology.

Following the departure of its founders BioNTech has taken a key strategic step. The company will continue to focus on mRNA the technology that made it globally known through its corona vaccine. Several people familiar with the matter confirmed the decision. Hundreds of employees are expected to move to a new company linked to the founders. Details on which research areas stay with BioNTech and which transfer to the founders form part of the separation plan. The report originates from Munich and is based on information available to Handelsblatt.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

2026년 06월 05일 AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Biontech to close nearly all production sites in Germany

German biotech firm Biontech plans to cut up to 1860 jobs in Germany. It will close multiple production sites and end Covid vaccine production there this year. Only pure office locations will remain.

Two gene-editing baby startups shut down after less than a year

2026년 04월 24일 AI에 의해 보고됨

Bootstrap Bio and Manhattan Genomics, biotech firms launched last year to pursue human embryo editing for preventing serious diseases, have closed their doors. The companies cited financial difficulties and internal conflicts as reasons for the shutdowns. The developments highlight challenges in the controversial field of gene-edited babies.

유럽

Siemens to abolish chief titles for executives

건강

Experimental mRNA vaccine shows protection against multiple ebola viruses

비즈니스

Bioinvent hosts kol event on ovarian cancer therapies

Caribou Biosciences presents car-t updates at healthcare conference

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

BASF opens integrated site in Zhanjiang

2026년 03월 22일 AI에 의해 보고됨

Chemical firm BASF opens its new integrated site in Zhanjiang, southern China, on Thursday. CEO Markus Kamieth views raw material supply as secure despite the Iran war and Hormuz Strait blockade.

2026년 06월 09일 09시 27분